Blood Test Detects Chronic Traumatic Encephalopathy During Life
|
By LabMedica International staff writers Posted on 22 Mar 2016 |

Image: The NanoSight LM10 instrument provides an easy-to-use, reproducible platform for nanoparticle characterization (Photo courtesy of Malvern Instruments).
Chronic traumatic encephalopathy (CTE) is a tauopathy associated with prior exposure to repetitive head impacts, such as those incurred through American football and other collision sports and diagnosis is made through neuropathological examination.
A method has been developed for measuring plasma exosomal tau. Exosomes are very small vesicles that are released from all types of cells throughout the body, including brain cells. They can be isolated in all body fluids, including plasma, a component of blood.
Scientists at Boston University School of Medicine (MA, USA) and their colleagues examined 78 former National Football League (NFL) players and a control group of 17 former non-contact sport athletes. Extracellular vesicles were isolated from plasma. Fluorescent nanoparticle tracking analysis was used to determine the number of vesicles staining positive for tau. Blood was drawn by venipuncture and immediately processed. Plasma samples were stored in 0.75 mL tubes at -80 °C, packed in dry ice, and shipped overnight in one batch to the Exosome Sciences laboratory (Monmouth Junction, NJ, USA).
Extracellular vesicles were isolated from the plasma samples by size exclusion chromatography. Plasma samples were applied to the column and it was then run isocratically. The elution was monitored at 280 nm and the void volume material (exosome fraction) was collected and pooled. The size profiles and concentrations of the chromatographically isolated exosomes were performed using the Nanosight LM10 instrument (Malvern Instruments Ltd.; Malvern, UK) equipped with a 405 nm laser, a scientific complementary metal-oxide-semiconductor (sCMOS) camera and Nanoparticle Tracking Analysis (NTA) software.
The method of measuring plasma exosomal tau is referred to as a TauSome. The groups did not differ in total plasma exosomes, but the NFL group had significantly higher plasma exosomal tau than the control group. The C-statistic is maximized when the plasma exosomal tau level is set to 0. Using 0 as a threshold resulted in 82% sensitivity, 100% specificity, 100% positive predictive value and 53% negative predictive value. The number of tau-positive plasma exosomes was significantly correlated with performance on standardized tests of memory and psychomotor speed; the higher the TauSome level, the worse the performance.
Jim Joyce, Founder of Exosome Sciences and Chairman and CEO of Aethlon Medical (San Diego, CA, USA), said, “We are extremely pleased that our initial study data has been published and we appreciate forthcoming opportunities to further advance our TauSome biomarker as a noninvasive solution to detect and monitor CTE in living individuals.” The study was published on February 10, 2016, in the Journal of Alzheimer's Disease.
Related Links:
Boston University School of Medicine
Exosome Sciences
Malvern Instruments Ltd.
A method has been developed for measuring plasma exosomal tau. Exosomes are very small vesicles that are released from all types of cells throughout the body, including brain cells. They can be isolated in all body fluids, including plasma, a component of blood.
Scientists at Boston University School of Medicine (MA, USA) and their colleagues examined 78 former National Football League (NFL) players and a control group of 17 former non-contact sport athletes. Extracellular vesicles were isolated from plasma. Fluorescent nanoparticle tracking analysis was used to determine the number of vesicles staining positive for tau. Blood was drawn by venipuncture and immediately processed. Plasma samples were stored in 0.75 mL tubes at -80 °C, packed in dry ice, and shipped overnight in one batch to the Exosome Sciences laboratory (Monmouth Junction, NJ, USA).
Extracellular vesicles were isolated from the plasma samples by size exclusion chromatography. Plasma samples were applied to the column and it was then run isocratically. The elution was monitored at 280 nm and the void volume material (exosome fraction) was collected and pooled. The size profiles and concentrations of the chromatographically isolated exosomes were performed using the Nanosight LM10 instrument (Malvern Instruments Ltd.; Malvern, UK) equipped with a 405 nm laser, a scientific complementary metal-oxide-semiconductor (sCMOS) camera and Nanoparticle Tracking Analysis (NTA) software.
The method of measuring plasma exosomal tau is referred to as a TauSome. The groups did not differ in total plasma exosomes, but the NFL group had significantly higher plasma exosomal tau than the control group. The C-statistic is maximized when the plasma exosomal tau level is set to 0. Using 0 as a threshold resulted in 82% sensitivity, 100% specificity, 100% positive predictive value and 53% negative predictive value. The number of tau-positive plasma exosomes was significantly correlated with performance on standardized tests of memory and psychomotor speed; the higher the TauSome level, the worse the performance.
Jim Joyce, Founder of Exosome Sciences and Chairman and CEO of Aethlon Medical (San Diego, CA, USA), said, “We are extremely pleased that our initial study data has been published and we appreciate forthcoming opportunities to further advance our TauSome biomarker as a noninvasive solution to detect and monitor CTE in living individuals.” The study was published on February 10, 2016, in the Journal of Alzheimer's Disease.
Related Links:
Boston University School of Medicine
Exosome Sciences
Malvern Instruments Ltd.
Latest Clinical Chem. News
- Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
- Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk
- Blood Test Detects Testicular Cancer Missed by Standard Markers
- Routine Blood Tests Identify Biomarkers Linked to PTSD
- Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges
- Routine Blood Count Ratio Linked to Future Alzheimer’s and Dementia Risk
- Label-Free Microfluidic Device Enriches Tumor Cells and Clusters from Pleural Effusions
- Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection
- Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation
- Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
- Study Finds ApoB Testing More Effective Than LDL for Guiding Lipid Therapy
- AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers
- Next Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
- Blood Metabolite Test Detects Early Cognitive Decline
- AI-Based Blood Test Diagnose Multiple Brain Disorders from Blood Sample
- Automated NfL Assay Supports Monitoring of Neurological Disorders
Channels
Clinical Chemistry
view channel
Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
Dementia affects more than 57 million people worldwide and is projected to nearly double within two decades, straining health systems and families. While biomarkers now enable accurate identification of... Read more
Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk
High blood pressure during pregnancy is common and can progress to pre-eclampsia, making close monitoring at antenatal visits essential. However, most risk assessment begins only after pregnancy has started.... Read moreMolecular Diagnostics
view channel
Liquid Biopsy Biomarkers Distinguish Inflammatory Breast Cancer and Support Monitoring
Inflammatory breast cancer is among the most aggressive forms of breast malignancy and remains challenging to diagnose and monitor. Obtaining tumor tissue can be difficult, and standard genome and RNA... Read more
Blood Test Maps Tumor Microenvironment to Predict Immunotherapy Response
Immunotherapy has transformed cancer care, yet durable benefit remains limited to a subset of patients, and clinicians still lack reliable tools to predict response before treatment begins.... Read more
Multiplex Respiratory Panel Integrates Automated Extraction to Streamline High-Volume Testing
Respiratory infections drive heavy testing volumes in clinical laboratories, where accurate, timely results across multiple pathogens are essential. Many labs are seeking to streamline workflows and increase... Read moreHematology
view channel
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more
Blood Test Enables Early Detection of Multiple Myeloma Relapse
Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read moreImmunology
view channel
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read more
T-Cell Senescence Profiling May Predict CAR T Responses
Chimeric antigen receptor (CAR) T-cell therapy can deliver striking, durable remissions, yet many patients experience minimal or no benefit. The quality of patient-derived cytotoxic T lymphocytes used... Read moreMicrobiology
view channel
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read moreTechnology
view channel
Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read more
New Platform Captures Extracellular Vesicles for Early Cancer Detection
Early diagnosis remains the most effective way to reduce cancer mortality, yet many screening tools miss disease at its earliest stages. Biomarkers shed by tumors into blood and other fluids can be scarce... Read moreIndustry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more








